The marketing authorisation for ProMeris has been withdrawn at the request of the marketing authorisation holder.
ProMeris : EPAR - Summary for the public (PDF/191.74 KB)
First published: 10/01/2007
Last updated: 14/07/2015
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
|Date of issue of marketing authorisation valid throughout the European Union||
Kent CT13 9NJ
08/07/2015 ProMeris - EMEA/V/C/000107 - IB/0012
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Ectoparasiticides for topical use, incl. insecticides
Treatment and prevention of flea infestations (Ctenocephalides canis and C. felis) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).